Cellectar Biosciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 10, 2026, reporting condensed consolidated financial statements and related disclosures.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $24,582,115 as of September 30, 2026, up from $13,196,033 as of December 31, 2025, according to the filing.
  • Total assets: The company reported total assets of $29,743,263 as of September 30, 2026, compared with $14,978,321 as of December 31, 2025.
  • Total liabilities: Total liabilities were $7,327,897 as of September 30, 2026, versus $5,059,134 as of December 31, 2025.
  • Shares outstanding: 10,039,183 shares of common stock, $0.00001 par value per share, were outstanding as of November 6, 2026.
  • Series D preferred stock: 111.11 shares were issued and outstanding as of December 31, 2025; 0.00 shares were issued and outstanding as of September 30, 2026.
  • Contracted research organization deposit: A new asset of $2,282,595 appeared on the balance sheet as of September 30, 2026, with no comparable balance as of December 31, 2025.
  • Warrant liability: The warrant liability decreased to $67,000 as of September 30, 2026, from $226,000 as of December 31, 2025.

Cellectar Biosciences Balance Sheet Changes for the September 30, 2026 Quarter

Cellectar Biosciences, Inc. (NASDAQ:CLRB), a smaller reporting company incorporated in Delaware and headquartered at 100 Campus Drive, Florham Park, New Jersey 07932, filed its quarterly report on Form 10-Q for the period ended September 30, 2026. The filing presents unaudited condensed consolidated balance sheets comparing positions as of September 30, 2026 and December 31, 2025.

According to the filing, cash and cash equivalents increased to $24,582,115 from $13,196,033 at year-end 2025, contributing to a rise in total current assets from $14,038,465 to $25,712,969. Total assets grew to $29,743,263 from $14,978,321 over the same period. A new line item, contracted research organization deposit, totaling $2,282,595, appeared among long-term assets as of September 30, 2026, with no balance recorded as of December 31, 2025. The operating lease right-of-use asset also rose to $1,384,274 from $360,671.

On the liabilities side, accounts payable and accrued liabilities increased to $5,729,302 from $4,423,548. The warrant liability declined to $67,000 from $226,000. The filing also noted that Series D preferred stock, which had carried a mezzanine equity value of $1,382,023 and 111.11 shares outstanding as of December 31, 2025, showed 0.00 shares issued and outstanding as of September 30, 2026. The filing contains forward-looking statements, which the company states are subject to risks and uncertainties that could cause actual results to differ materially; these are the company's own statements and subject to its cautionary language.

What Was Disclosed

Cellectar Biosciences filed a Form 10-Q for the quarter ended September 30, 2026, disclosing unaudited balance sheet data showing higher cash, total assets, and a new contracted research organization deposit, alongside a reduction in warrant liability and the elimination of outstanding Series D preferred stock.